Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I. Silverberg, Christopher G. Bunick, Melinda Gooderham et al.|Dermatology and Therapy|2025Cited by 9
Mo1837 – Effect of Upadacitinib on Extra-Intestinal Manifestations in Patients with Moderate to Severe Crohn’s Disease: Data from the Celest StudyLaurent Peyrin‐Biroulet, Kristina Kligys, Silvio Danese et al.|Gastroenterology|2019Cited by 2
Tu1727 – Rapidity of Symptomatic and Inflammatory Biomarker Improvements Following Upadacitinib Induction Treatment: Data from the U-Achieve StudyGeert D’Haens, Séverine Vermeire, Edward V. Loftus et al.|Gastroenterology|2019Cited by 1
817 Identification of Biomarkers and Mechanistic Insight for Upadacitinib in Crohn’s Disease: Serum Inflammatory Mediator Analysis From the Phase 2b CELEST StudyVermeire Séverine, Silvio Danese, Heath Guay et al.|The American Journal of Gastroenterology|2019Cited by 0